HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
AbbVie announced that the FDA has approved a new packaging option for AndroGel (testosterone gel) 1.62%. Besides the previously approved metered-dose pump packaging, Androgel 1.62% will also be ...
CHICAGO — The Food and Drug Administration has approved a new pocket-sized packet option for a testosterone-replacement therapy made by AbbVie, the drug maker said Friday. AbbVie announced the ...
ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless ...
PARSIPPANY, N.J. — Just a week after the Supreme Court heard the Federal Trade Commission's lawsuit over its deal with AbbVie to sell a generic version of a testosterone-replacement therapy, Actavis ...
February 15, 2012 (UPDATED February 16, 2012) — The US Food and Drug Administration (FDA) yesterday approved a low-dose once-daily testosterone transdermal gel (Bio-T-Gel, Teva Pharmaceuticals) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback